Key facts
- Phitech (Decision/Risk Analysis)’s last known valuation is $5.6M (Feb 2024).
- It has raised $3.5M; the latest was Later Stage VC ($2.4M) in Apr 2026.
- Notable investors include Alchemist Accelerator, IstCapital, Eksim Venture, Adem Akkaya, Ahmet Atasoy — 30 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 30 names
- ·Watchlist + deal alerts for Phitech (Decision/Risk Analysis)
- ·The full record, as it builds
Funding rounds
No funding rounds for Phitech (Decision/Risk Analysis) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Phitech (Decision/Risk Analysis)
Developer of genomic algorithms designed to extract critical information for diagnostic decision-making. The company offers translation of genome-wide molecular data such as genomics, transcriptomics, epigenomics, and microbiomics into biotechnology systems, enabling healthcare professionals to make diagnostic decision-making and use in precision medicine.
- Sector
- Healthcare
- HQ
- Kocaeli, Turkey
- Employees
- 22
- Website
- phitech.bio/
- Ownership
- Privately Held (backing)
Phitech (Decision/Risk Analysis) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phitech (Decision/Risk Analysis) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phitech (Decision/Risk Analysis) in its N-PORT filings yet. We sweep new filings monthly.